This website is for healthcare professionals - NIOX PRO® is available in the following countries.

FeNO for Primary Care

A safe and easy test to instantly transform your asthma care

Asthma diagnosis is 7x more likely with a high FeNO level.3

Key highlights:

Using FeNO testing as your asthma risk estimator can help reduce exacerbations by up to 50%.4

Understanding the level of inflammation with FeNO can lead to improved asthma care.

Studies have shown that FeNO testing is a cost-effective way to improve patient outcomes.

Nobel Prize-Winning Science

FeNO stands for fractional exhaled nitric oxide (NO). NO is a molecule produced by the lungs that can be measured in exhaled breath. The use of NO in medicine was a real breakthrough, leading to a Nobel Prize in 1998.

Asthma: it's about inflammation

Although asthma is traditionally diagnosed with tools that measure airway obstruction, it's actually an inflammatory condition.1

As research progresses, opinion is changing. It is now understood that up to 84% of asthma patients have Type 2 airway inflammation.2

Airway Inflammation

See inflammation clearly with FeNO

Understanding the level of inflammation with FeNO can lead to improved asthma care. FeNO levels are elevated in asthma and can provide healthcare professionals with the opportunity to see inside a patient’s lungs at the point-of-care.

More accurate diagnosis

With half of asthma cases misdiagnosed, lung function testing is not enough to make a decision.2 Asthma diagnosis is 7x more likely with a high FeNO level.3

This is Lucy

She gets breathless when she runs and occasionally at night. Lucy made an appointment to see her doctor to understand what was going on.

The doctor performed routine lung function testing and would have ruled out asthma. However when Lucy performed a FeNO test, the result was 73ppb, indicating airway inflammation.

This suggests that Lucy may have asthma.

FeNO and diagnosis

Better managament

A high FeNO level indicates a greater risk of exacerbation. Using FeNO testing as your asthma risk estimator can help reduce exacerbations by up to 50%.4

This is Victor

He has had asthma since the age of 3 and is prescribed an inhaled corticosteroid. Victor still experiences exacerbations and recently visited his doctor.

The doctor wanted to check whether Victor was using his inhaler properly and offered him a FeNO test. Victor had a FeNO level of 163ppb, showing he is non-adherent to his medication and at risk of severe exacerbations. Seeing this number showed Victor how bad the situation actually was.

As part of his asthma management plan, Victor tested his FeNO regularly with the aim of reducing his FeNO to a normal level. Seeing his FeNO level reduce at every appointment motivated Victor to keep taking his medication. Victor’s FeNO is now 24ppb, his inflammation is under control and he has not had an asthma attack in the last year.

FeNO and exacerbations

One size doesn't fit all

Exacerbation risks can be increased by modifiable factors such as high airway inflammation, reduced lung function, poor adherence to ICS or inadequate inhaler technique.1 Elevated FeNO values are associated with 3.2x greater risk of exacerbations when compared to low FeNO levels.4 Aiming to reduce high FeNO levels can help improve patient outcomes.5

Severe Asthma

Ready for FeNO by NIOX®?

Request a quote for a device today with our simple and easy to use quotation tool. Used by thousands of healthcare professionals, NIOX® is the global device of choice for FeNO testing.6

Request a Quote

Discover FeNO Testing

Learn about FeNO with our free app

Why NIOX®

Explore the Gold Standard technology

Understand FeNO Scores

Use our interpreting FeNO calculator

NIOX® Customer Support and Training

At NIOX® we are passionate about providing excellent support and training.

References:

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2021 update.
2. Kavanagh J et al. Over- and under-diagnosis in asthma. Breathe (Sheff). 2019;15(1):e20-e27.
3. Wang Z et al. Agency for Healthcare Research and Quality (AHRQ). The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management. Comparative Effectiveness Reviews, 197. 2017.
4. Petsky HL et al. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110-1119.
5. Dweik RA et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-15.
6. NIOX®. Data on File; MKT-DOF-007. 2026.
7. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
8. NIOX®. NHS England Asthma data 2022 (AST001). QOF database. Available at; https://www.gpcontract.co.uk/browse/ENG/Asthma/22. Accessed; May 2023.

© Copyright NIOX Group plc. PP-NXWW-WW-0283. May 2024.
NIOX Lingua™ utilises automated translation and may include occasional inaccuracies.
uk-flag
English
france-flag
Français
spain-flag
Español
romania-flag
Română
japan-flag
日本語
portugal-flag
Português
czech-republic-flag
Čeština
south-korea-flag
한국어
sweden-flag
Svenska
italy-flag
Italiano

albania-flag
Shqip
saudi-arabia-flag
العربية
azerbaijan-flag
Azərbaycan dili
basque-flag
Euskara
bangladesh-flag
বাংলা
bulgaria-flag
Български
catalan-flag
Català
denmark-flag
Dansk
netherlands-flag
Nederlands
esperanto-flag
Esperanto
estonia-flag
Eesti
finland-flag
Suomi
galician-flag
Galego
greece-flag
Ελληνικά
israel-flag
עברית
india-flag
हिन्दी
hungary-flag
Magyar
indonesia-flag
Bahasa Indonesia
ireland-flag
Gaeilge
kyrgyzstan-flag
Кыргызча
latvia-flag
Latviešu
lithuania-flag
Lietuvių
malaysia-flag
Bahasa Melayu
norway-flag
Norsk
iran-flag
فارسی
poland-flag
Polski
brazil-flag
Português (Brasil)
russia-flag
Русский
slovakia-flag
Slovenčina
slovenia-flag
Slovenščina
philippines-flag
Tagalog
thailand-flag
ไทย
turkey-flag
Türkçe
ukraine-flag
Українська
pakistan-flag
اردو
vietnam-flag
Tiếng Việt